Skip to main content

Table 1 Ongoing phase I/II studies testing PARP-inhibitors, immune checkpoint inhibitors and epigenetic drugs as monotherapy or in combinatorial regimen in advanced urothelial cancer

From: New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment

ClinicalTrials.gov
identifier
Phase Patients PARP inhibitor Checkpoint inhibitor Epigenetic drug References
NCT03448718 II Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations Olaparib    N/A
NCT03375307 II Metastatic or Advanced Urothelial Cancer With DNA-Repair Defects Olaparib    N/A
NCT03397394 (UCLA) II Locally Advanced or Metastatic Urothelial Carcinoma Rucaparib    N/A
NCT02736266 II Muscle-invasive Urothelial Bladder Carcinoma   Pembrolizumab   N/A
NCT02951767 (IMvigor 210) II Locally Advanced or Metastatic Urothelial Bladder Cancer   Atezolizumab   36
NCT02108652 (IMvigor 211) II Locally Advanced or Metastatic Urothelial Bladder Cancer   Atezolizumab   79
NCT02546661 (BISCAY) Ib Muscle Invasive Bladder Cancer Olaparib Durvalumab   N/A
NCT03534492 (NEODURVARIB) II Prior to Surgery of Resectable Urothelial Bladder Cancer Olaparib Durvalumab   N/A
NCT03459846 (BAYOU) II Advanced, Platinum-Ineligible Bladder Cancer Olaparib Durvalumab   N/A
NCT02619253 I Advanced renal or urothelial cell carcinoma   Pembrolizumab Vorinostat N/A
NCT03179943 II Advanced, Platinum-Ineligible Bladder Cancer   Atezolizumab Guadecitabine N/A